↑ Rising
Business
Exclusive | FDA Gives Third Rare-Disease Drug Another Shot, Regenxbio Says
The FDA is allowing Regenxbio to resubmit its gene therapy for Hunter syndrome, marking a reversal of a previous rejection.
2 trends tracked about this subject — the full history, oldest to newest below.
The FDA is allowing Regenxbio to resubmit its gene therapy for Hunter syndrome, marking a reversal of a previous rejection.
A lupus treatment borrowed from cancer therapy is putting patients into remission—with one calling it life-changing.